Adjusted EPS Beat
Reported adjusted earnings per share of $7.23 in Q1, materially ahead of expectations and supporting an updated full-year outlook of greater than $18.25 per share.
Revenue Growth and Strong Cash Flow
Total revenues of $111.7 billion, up 2% year-over-year, with operating cash flow of $8.9 billion in the quarter (1.4x net income).
Improved Medical Care Ratio
Reported medical care ratio improved to 83.9% from 84.8% in Q1 2025 (about 90 basis points improvement), driven by pricing discipline, medical cost management and favorable reserve development.
Optum Health Operational Turnaround
Optum Health adjusted earnings of $1.3 billion reflecting pricing and operational improvements; examples include a ~35% reduction in skilled nursing facility admissions (in the initial month in one region), clinical reviews up >50% and a 12% YoY increase in patient-facing hours.
Digital Adoption and Prior Authorization Automation
Almost 50% of members registered for UHC digital access; 73 million digital visits in Q1 (up 42% over two years); >80% of consumer contacts are digital. Prior authorization progress: ~95% of requests submitted electronically, ~50% processed in real time and >90% approved on average within 1 business day.
Optum Rx Client Wins and Efficiency Gains
Onboarded more than 800 new Optum Rx clients to start the year; contact center volume down 25% via digital/AI self-service with member satisfaction over 95%. PreCheck PA reduced prescription approval time from >8 hours to <30 seconds and cut denials for missing information by 68% and appeals by 88%.
Material AI Investment with Early Traction
Plan to invest nearly $1.5 billion in AI-related initiatives in 2026; Optum Insight/AI products showing traction (Optum Real 0.5 billion YTD transactions, targeting >2.5 billion by year-end) and expected conservative 2:1 return on many programs over next few years.
Capital Allocation & Balance Sheet Progress
Debt-to-capital ratio improved to 42.9% (on track to 40% year-end target). Initiated share repurchases earlier than planned with at least $2 billion expected to be deployed by end of Q2 and continued discipline on M&A and strategic capital deployment.